Effect of Entrectinib on bone metabolism in vitro

24.11.2021 bis 01.10.2023

Entrectinib, a potent, CNS-active, TRK and ROS1 inhibitor is known to increase the risk of spontaneous bone fractures, particularly in pediatric patients. In this study the underlying mechanisms of this event should be investigated, which should help safe dosing of children receiving this drug. To achieve this, it should be first be proved that effects of Entrectinib can be displayed in in vitro bone model. To investigate the effects of Entrectinib on bone, a co-culture cell model representing juvenile and adult bone will be established.